Cell and Gene Outsourcing

31. Beyond The Starting Material: A Path To GMP Manufacturing Success 9/21/2026

    Explore how starting material decisions affect cell therapy development, tech transfer, and GMP readiness, as well as practical guidance for aligning material requirements with manufacturing processes.

32. End-To-End Advanced Therapy CDMO Services 9/21/2026

    A capabilities overview of advanced therapy CDMO services spanning viral vector, cell therapy, and mRNA development, manufacturing, cold chain logistics, and integrated program management across a global site network.

33. The Phase 2 Manufacturing Wall: The CMC Risk Hiding In Plain Sight 9/17/2026

    Hidden gaps in process maturity and organizational alignment can derail development. Discover how to identify risks early and improve readiness for key milestones.

34. GLP-1 Peptides In Asia: Expanding Access And Opportunity 9/17/2026

    Asia's growing role in the GLP-1 market presents new opportunities and challenges. Learn how regulatory preparedness, scalable manufacturing, and robust quality systems can enable growth.

35. Why You Should Measure Comparability Debt Before Ever Starting A Study 9/17/2026

    When analytical capability and process understanding fail to keep pace with a drug candidate, the technical uncertainty creates debt that's difficult to pay down.

36. Forging The Future Of RNA Therapeutics Through Science, Systems And Scales 9/16/2026

    RNA innovation is shifting from discovery to scalable development. Explore advances in delivery, manufacturing, analytics, regulation, and commercialization driving broader therapeutic impact.

37. Viral Vector Services 9/15/2026

    Fast-track your Gene Therapies from cutting-edge process development to commercial success with advanced viral vector manufacturing solutions!

38. GLP-1 Peptides Around The World Part III: EU Evolution – Expanded Expectations And Emerging Enforcement 9/15/2026

    Navigating GLP-1 development in Europe? Discover how stricter CMC, Annex 1, serialization, and supply chain requirements are influencing manufacturing strategies.

39. Making Complex Science Dependable 9/15/2026

    Advance small molecule programs with the right mix of scientific expertise, scalable manufacturing, regulatory readiness, and analytical support from discovery to launch.

40. Advancing Biologic Drug Products With Integrated Development And Analytical Services At CPHI Worldwide 9/15/2026

    Explore how integrated formulation, analytical, predictive, and GMP testing capabilities can help complex biologics advance toward robust manufacturing, regulatory readiness, and more.